This report is an in-depth financial evaluation of the GlobalBiopharmaceutical Companies. Using the unique Plimsoll method of analysis, each of the top 200 companies included is individually assessed and ranked against each other and compared to industry averages.Using the most up-to-date financial information available, the two-page per company analysis provides detailed financial analysis for each organisation. The following are some of the key findings of this new report:
85 of the 200 companies analysed have been rated as Danger
52 companies are ripe for takeover
123 companies achieved greater than 10% increase in sales last year.
78 companies made a pre-tax loss.
61 companies saw sales fall last year.
Our analysis gives you this unrivalled market and company intelligence using a simple graphical, numeric and model. Each company is individually analysed in both the companys own currency, and USD ($) for ease of use. These individual analyses highlight a companys strengths and weaknesses instantly.
Along with individual company information, this report also contains a comprehensive study of the market, based on the companies analysed. This key information includes:
- Best trading partners (based on commercial and financial strength)
- Sales growth (highest sales, growth rate, size of market based on the companies analysed, average growth)
- Profitability (Profit return on assets, pre-tax profit margins, industry average)
- Fastest growing companies (performance matrix)
Companies can change at an alarming rate in a very short space of time be sure to check out the performance of the 85 companies we rate as Danger to see how these companies have declined over 4 years. The Plimsoll Global Analysis will give you an in-depth assessment of the Global Biopharmaceutical Companies industry instantly. Whether you wish to benchmark your own companys results, study the industry in more depth or have a vast array of industry intelligence at your disposal, this report is the ideal resource.